The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro

The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro

Sonnemann J; Eckervogt V; Truckenbrod B; Boos J; Winkelmann W; van Valen F

Anti-cancer Drugs

2003

Humans; Comparative Study; Dose-Response Relationship; Drug; Sarcoma; Antineoplastic Agents/pharmacology; Cell Division/drug effects; Cell Line; Clodronic Acid/pharmacology; Diphosphonates/pharmacology; Ewing's; Lovastatin/analogs & derivatives/pharmacology; Tumor

The MTT assay was used to measure the effects of pamidronate, clodronate and mevastatin on the cell viability of Ewing's sarcoma cell lines 6647, CADO-ES-1, ES-2, ES-3, RD-ES, SK-ES-1, STA-ET-2.1 and VH-64. Treatment of these cells with pamidronate inhibited cell viability in a time- and dose-dependent manner. After a 72-h incubation period with 50 microM pamidronate, cell numbers were reduced by up to 80%, whereas the monophosphonate analog 3-aminopropyl phosphonate had no effect at concentrations up to 2 mM. Clodronate reduced cell viability by maximally 40% at 1 mM. These data provide the first evidence for a direct growth-inhibitory effect of pamidronate on Ewing's sarcoma cells. Hence, pamidronate definitely merits a more thorough exploration into its potential use in the therapy of patients with Ewing's sarcoma.

2003

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Journal Article

Backlog